Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

Researchers from Ocean University of China and Qingdao Marine Science and Technology Center published data from a preclinical study that investigated the impact of the quinazolinone derivative MR-2938 ...

They applied yohimbine, an antagonist of ADRA2A, to mice with DSS-induced colitis. Compared with the non-treatment controls, yohimbine treatment significantly ameliorated the phenotypes of DSS ...

TP-317, a Novel BLT1 Agonist Oral Therapy for Inflammatory Bowel Disease, Exhibits Anti-Inflammatory and Epithelial Barrier Protective Efficacy in Murine DSS Colitis and TNFΔARE Ileitis Abstract ...

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company ...

showing its efficacy in reducing colitis symptoms in a DSS mouse model without central nervous system toxicity. PALI-2108 is an orally administered, colon-specific phosphodiesterase-4 (PDE4 ...

Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model” at the Crohn’s & Colitis Congress in San Francisco, CA. The poster is available on the Company’s website.